Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Intestinal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm

Cancer Family

Intestinal Neoplasm

CI-CAN-00000209Explore in graph →

Non-malignant1,892 active trials21 approved drugs383 evidence items

NCIt: C3141
MeSH: D007414

Overview
Statistics
Survival
Genomics28
Variants & evidence383
Drugs80
Trials9155
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (371)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 326–350 of 371 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
· J Clin Invest · 2013 · PMID 23867504 · validated civic_curation pubmed
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
· Oncogene · 2011 · PMID 20956938 · validated civic_curation pubmed
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
· J Clin Invest · 2011 · PMID 21985784 · validated civic_curation pubmed
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
· Nature · 2012 · PMID 22281684 · validated civic_curation pubmed
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
· Clin Cancer Res · 2013 · PMID 23549875 · validated civic_curation pubmed
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
· Clin Cancer Res · 2012 · PMID 22392911 · validated civic_curation pubmed
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
· Mol Cancer Ther · 2016 · PMID 27364904 · validated civic_curation pubmed

Showing 326–350 of 371 publications

← Previous
1
…
13
14
15
Next →

Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.

· Sci Rep · 2016 · PMID 27197561 · validated civic_curation pubmed

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

· Nature · 2017 · PMID 28783719 · validated civic_curation pubmed

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

· Clin Cancer Res · 2015 · PMID 26296355 · validated civic_curation pubmed

A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.

· Cancer Res · 2017 · PMID 28512242 · validated civic_curation pubmed

Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.

· Anticancer Drugs · 2014 · PMID 25089570 · validated civic_curation pubmed

Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.

· Digestion · 2013 · PMID 24135816 · validated civic_curation pubmed

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

· Cell Cycle · 2012 · PMID 22262166 · validated civic_curation pubmed

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.

· Clin Cancer Res · 2011 · PMID 21890455 · validated civic_curation pubmed

OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer.

· Oncol Rep · 2015 · PMID 26398480 · validated civic_curation pubmed

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.

· Oncotarget · 2016 · PMID 26716414 · validated civic_curation pubmed

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

· Future Oncol · 2015 · PMID 26161928 · validated civic_curation pubmed

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.

· Clin Cancer Res · 2018 · PMID 29588308 · validated civic_curation pubmed

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.

· PLoS One · 2015 · PMID 26709701 · validated civic_curation pubmed

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

· Sci Signal · 2010 · PMID 21098728 · validated civic_curation pubmed

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

· Mol Cancer Res · 2014 · PMID 24296758 · validated civic_curation pubmed

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

· Cancer Discov · 2018 · PMID 29196463 · validated civic_curation pubmed

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

· Mol Cancer Res · 2009 · PMID 19737969 · validated civic_curation pubmed

Gingras et al. Cell Rep 2016

· 2016 · PMID 26804919 · validated cbioportal_study pubmed